Company News: Lilly and Incyte

Share this article:
Eli Lilly forged a deal with Incyte, gaining rights to develop and globally commercialize Incyte's oral JAK1/JAK2 inhibitor, INCB28050, and certain follow-on compounds, for inflammatory and autoimmune diseases. INCB28050 is currently in Phase II trials for rheumatoid arthritis. Terms call for Incyte to receive a $90-million upfront payment and up to $665 million in potential milestones, plus royalties on future sales.
Teva entered an agreement to in-license Phase-III oncology drug OGX-011 from OncoGenex Pharmaceuticals as well as purchase shares in the biopharma firm. OGX-011, for use in enhancing chemotherapy, is scheduled to begin Phase III trials in 2010 and 2011 among patients with advanced prostate cancer and non-small cell lung cancer. Teva will provide OncoGenex with a $60-million initial cash payment, including a $10-million equity investment in OncoGenex common stock at a price of $37.38 per share, upfront payment of $20 million and prepayment of $30 million for OncoGenex's contribution to OGX-011 development costs. OncoGenex will be eligible to receive up to $370 million in milestone payments and tiered royalties on sales. Teva is responsible for all commercialization and development expenses, and OncoGenex retains an option to co-promote OGX-011 in the US and Canada.

Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.